Travere Therapeutics (TVTX) Research & Development (2013 - 2026)

Travere Therapeutics (TVTX) has 14 years of Research & Development data on file, last reported at $57.1 million in Q1 2026.

• Quarterly Research & Development rose 21.76% year-over-year to $57.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $216.2 million (up 0.58% YoY) and the FY2025 annual result came in at $206.0 million, down 5.28% from the prior year.
• Research & Development fell to $57.1 million in Q1 2026, from $57.9 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $66.5 million in Q2 2023 to a low of $46.9 million in Q1 2025.
• A 5-year average of $56.3 million and a median of $57.1 million in 2022 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2024 — Research & Development decreased 18.29% — and 2026, when it increased 21.76%.
• Tracing TVTX's Research & Development over 5 years: stood at $58.1 million in 2022, then climbed by 2.86% to $59.7 million in 2023, then gained by 3.88% to $62.1 million in 2024, then retreated by 6.76% to $57.9 million in 2025, then declined by 1.34% to $57.1 million in 2026.
• The last three Research & Development figures came in at $57.1 million (Q1 2026), $57.9 million (Q4 2025), and $51.9 million (Q3 2025), per Business Quant data.